RCT | Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.
21 Jul, 2022 | 13:25h | UTCPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone. https://t.co/5urffgHdFb pic.twitter.com/2GlmJuYZJz
— NEJM (@NEJM) July 20, 2022